Fluorine-decorated graphene quantum dots (F@GQDs) will be herein explored as a material platform for application in photodynamic therapy (PDT). GQDs have been extensively studied in biomedical areas such as bioimaging, bio-sensing and photothermal therapy due to their superior op… » Read More
Precision oncology uses molecular and clinical information to select the most effective therapies while minimizing unnecessary toxicity. Genetic testing identifies inherited cancer predispositions andtumor-specific mutations, enabling earlier detection, more accurate prognosticat… » Read More
Background: KRAS G12D is one of the most prevalent oncogenic drivers in pancreatic and colorectal cancers and remains a challenging therapeutic target because of its high affinity for GTP and the absence of a reactive residue for covalent inhibition. Identifying non-covalent inhi… » Read More
The prognosis of breast cancer remains unpredictable despite of frequent change in treatment protocol since last few decades. As we understand the heterogenous nature of the disease, complex tumor biology etc. the treatment protocols have changed. There is an unprecedented transf… » Read More
Scientific program for this day is coming soon.
Title : Nanomedicine in over 45,000 patients and no cancer
Thomas Jay Webster, Brown University, United States
Nanomedicine is the use of nanomaterials to improve disease prevention, detection, and treatment which has resulted in hundreds of US FDA approved medical products. While nanomedicine has been around for several decades, new technological advances are pushing its boundaries. For … » Read More
Title : Evolving concepts of breast cancer management and recent trends
Manmohan Agrawal, Pushpadi Hospital, India
The prognosis of breast cancer remains unpredictable despite of frequent change in treatment protocol since last few decades. As we understand the heterogenous nature of the disease, complex tumor biology etc. the treatment protocols have changed. There is an unprecedented transf… » Read More
Title : Long-read sequencing reveals dynamic features of human malignancies
Jianhua Luo, University of Pittsburgh School of Medicine, United States
The protein diversity of mammalian cells is determined by arrays of isoforms from genes. Genetic mutation is essential in species evolution and cancer development. Accurate Long-read transcriptome sequencing at single-cell level is required to decipher the spectrum of protein exp… » Read More
Title : Tumor resectability and pathologic response after neoadjuvant long-course chemoradiotherapy for locally advanced rectal cancer in a resource-limited setting
Samrawit S Halake, Kampala International University, Uganda
Purpose: In resource-limited settings, locally advanced rectal cancer (LARC) often presents at advanced stages. Long-course chemoradiotherapy (LCCRT) remains a cornerstone of neoadjuvant therapy, yet outcome data from such settings remain limited. This study assessed tumor resect… » Read More
Title : Personalized and Precision Medicine (PPM) through the view of biodesign-inspired translational research: An option for clinical oncologists, caregivers and consumers to realize the potential of genomics-informed care to secure human biosafety
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
A new systems approach to diseased states and wellness result in a new branch in the healthcare ser-vices, namely, personalized and precision medicine (PPM). Meanwhile, the era of genomics-based med-icine and thus genomics biomarkers promises to provide molecular tests that will … » Read More
Title : Personalized and precision medicine as a unique avenue to have the healthcare model renewed to secure national biosafety: To get cancer treated or cured?
Sergey Suchkov, N.D. Zelinskii Institute for Organic Chemistry of the Russian Academy of Sciences, Russian Federation
To achieve the implementation of Personalized & Precision Oncology (PPO), it is necessary to create a fundamentally new strategy based upon the recognition of biomarkers long before the disease clinically manifests itself. And personalized tumor molecular profiles (uniting genomi… » Read More
Title : Will be updated soon…
Yan Leyfman, NYP- Meyer Cancer Center, United States